{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:36:02Z","timestamp":1790004962690,"version":"4.0.1"},"reference-count":46,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Targeting the interleukin 17 (IL-17) axis is efficacious in psoriasis and spondyloarthritis (SpA), but not in rheumatoid arthritis (RA). We investigated potential differences in tissue expression and function of IL-17A and IL-17F in these conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>mRNA expression of cytokines and their receptors was assessed by quantitative PCR in psoriasis skin samples, in SpA and RA synovial tissue (ST) samples and in fibroblast-like synoviocytes (FLS). Cytokines were measured in synovial fluid (SF) and FLS supernatants by ELISA. FLS were stimulated with IL-17A or IL-17F cytokines supplemented with tumor necrosis factor (TNF), or with pooled SF from patients with SpA or RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Levels of <jats:italic>IL-17A<\/jats:italic> (<jats:italic>P<\/jats:italic> = 0.031) and <jats:italic>IL-17F<\/jats:italic> (<jats:italic>P<\/jats:italic> = 0.017) mRNA were lower in psoriatic arthritis ST compared to paired psoriasis skin samples. The level of <jats:italic>IL-17A<\/jats:italic> mRNA was 2.7-fold lower than that of IL-17F in skin (<jats:italic>P<\/jats:italic> = 0.0078), but 17.3-fold higher in ST (<jats:italic>P<\/jats:italic> &lt; 0.0001). In SF, the level of IL-17A protein was 37.4-fold higher than that of IL-17F [median 292.4 (IQR 81.4\u2013464.2) vs median 7.8 (IQR 7.7\u20138.7) pg\/mL; <jats:italic>P<\/jats:italic> &lt; 0.0001]. IL-17A and IL-17F mRNA and protein levels did not differ in SpA compared to RA synovitis samples, and neither were the IL-17 receptors <jats:italic>IL-17RA<\/jats:italic> and <jats:italic>IL-17RC<\/jats:italic>, or the TNF receptors <jats:italic>TNFR1<\/jats:italic> and <jats:italic>TNR2<\/jats:italic>, differentially expressed between SpA and RA ST, nor between SpA and RA FLS. SpA and RA FLS produced similar amounts of IL-6 and IL-8 protein upon stimulation with IL-17A or IL-17F cytokines, supplemented with 1 ng\/ml TNF. Pooled SpA or RA SF samples similarly enhanced the inflammatory response to IL-17A and IL-17F simulation in FLS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The IL-17A\/IL-17F expression ratio is higher in SpA synovitis compared to psoriasis skin. Expression of IL-17A and IL-17F, and the functional response to these cytokines, appear to be similar in SpA and RA synovitis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.190571","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T17:25:39Z","timestamp":1579109139000},"page":"1606-1613","source":"Crossref","is-referenced-by-count":17,"title":["Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis"],"prefix":"10.3899","volume":"47","author":[{"given":"Sijia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris C.","family":"Blijdorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonieke J.J.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowann","family":"Bowcutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia E.","family":"Latuhihin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen G.H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya G.","family":"Yeremenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L.P.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"2022062017050993000_47.11.1606.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"2022062017050993000_47.11.1606.2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2018.04.001","article-title":"Cytokine targeting in rheumatoid arthritis","volume":"206","author":"Bui","year":"2019","journal-title":"Clin Immunol"},{"key":"2022062017050993000_47.11.1606.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2022062017050993000_47.11.1606.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53"},{"key":"2022062017050993000_47.11.1606.5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40744-017-0086-y","article-title":"Secukinumab in active rheumatoid arthritis after anti-TNF alpha therapy: a randomized, double-blind placebo-controlled phase 3 study","volume":"4","author":"Tahir","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2022062017050993000_47.11.1606.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4347"},{"key":"2022062017050993000_47.11.1606.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141271"},{"key":"2022062017050993000_47.11.1606.8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheum"},{"key":"2022062017050993000_47.11.1606.9","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1390605"},{"key":"2022062017050993000_47.11.1606.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209831"},{"key":"2022062017050993000_47.11.1606.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2022062017050993000_47.11.1606.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2022062017050993000_47.11.1606.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"2022062017050993000_47.11.1606.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2022062017050993000_47.11.1606.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2022062017050993000_47.11.1606.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"2022062017050993000_47.11.1606.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211555"},{"key":"2022062017050993000_47.11.1606.18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jcma.2012.05.006","article-title":"Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis","volume":"75","author":"Chen","year":"2012","journal-title":"J Chin Med Assoc"},{"key":"2022062017050993000_47.11.1606.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.038"},{"key":"2022062017050993000_47.11.1606.20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3233\/BMR-170903","article-title":"Relationship of hematologic markers with IL-17 and IL-1 beta in patients with rheumatoid arthritis","volume":"31","author":"Sa\u011f","year":"2018","journal-title":"J Back Musculoskelet Rehabil"},{"key":"2022062017050993000_47.11.1606.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2008.12.024"},{"key":"2022062017050993000_47.11.1606.22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022062017050993000_47.11.1606.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0801967"},{"key":"2022062017050993000_47.11.1606.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"2022062017050993000_47.11.1606.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2022062017050993000_47.11.1606.26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11926-013-0317-3","article-title":"Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis","volume":"15","author":"Taylor","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2022062017050993000_47.11.1606.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2022062017050993000_47.11.1606.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2022062017050993000_47.11.1606.29","doi-asserted-by":"publisher","DOI":"10.1007\/s100670050134"},{"key":"2022062017050993000_47.11.1606.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2013.03.006"},{"key":"2022062017050993000_47.11.1606.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.24406"},{"key":"2022062017050993000_47.11.1606.32","first-page":"155","article-title":"Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies","volume":"14","author":"Schlaak","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2022062017050993000_47.11.1606.33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Rheum Dis"},{"key":"2022062017050993000_47.11.1606.34","first-page":"S1065","article-title":"Interleukin-17 serum levels are associated with markers of systemic inflammation in patients with active ankylosing spondylitis","volume":"65","author":"Poddubnyy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022062017050993000_47.11.1606.35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2014-eular.5815","article-title":"Serum level IL-23, IL-18, IL-17A, IL-17F, IL-12, IL-6 in psoriatic arthritis PSA patients hospitalized at the Rheumatology Clinic of Medical University in Wroclaw, Poland","volume":"73","author":"Sokolik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022062017050993000_47.11.1606.36","first-page":"2285","article-title":"Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy","volume":"34","author":"Singh","year":"2007","journal-title":"J Rheumatol"},{"key":"2022062017050993000_47.11.1606.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1737-y"},{"key":"2022062017050993000_47.11.1606.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-211055.22"},{"key":"2022062017050993000_47.11.1606.39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022062017050993000_47.11.1606.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"2022062017050993000_47.11.1606.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2022062017050993000_47.11.1606.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"2022062017050993000_47.11.1606.43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/art.40736","article-title":"Expansion of interleukin-22- and granulocyte-macrophage colony-stimulating factor-expressing, but not interleukin-17A-expressing, Group 3 innate lymphoid cells in the inflamed joints of patients with spondyloarthritis","volume":"71","author":"Blijdorp","year":"2019","journal-title":"Arthritis Rheumetol"},{"key":"2022062017050993000_47.11.1606.44","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3HI1215-542R"},{"key":"2022062017050993000_47.11.1606.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.33396"},{"key":"2022062017050993000_47.11.1606.46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/key331","article-title":"Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content","volume":"58","author":"Chen","year":"2019","journal-title":"Rheumatology"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:06:55Z","timestamp":1655770015000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.3899\/jrheum.190571"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190571","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]}}}